7 products found
Gritstone Bio Products
-
Scientific Platform
-
Gritstone - Model EDGE - Proprietary Technologies
The first pillar of our immunotherapy is our understanding of antigens and neoantigens, and specifically which ones will be transcribed, translated, processed and presented on a cell surface by Human leukocyte antigen (HLA) molecules; and therefore will be visible to T cells. We accomplish this through the use of Gritstone EDGETM, our proprietary machine learning-based ...
-
Our Pipeline
-
Granite - Patient-Specific Neoantigen Immunotherapy
Our first oncology product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. It is being evaluated in the Phase 2 portion of a Phase 1/2 clinical study in combination with checkpoint inhibitors for patients with microsatellite stable colorectal cancer (MSS CRC) who have progressed on FOLFOX/FOLFIRI therapy and a second cohort for patients with gastro-esophageal cancer who have progressed on chemotherapy. GRANITE was granted Fast Track ...
-
Slate - Shared Neoantigen Immunotherapy
Our second product candidate, SLATE, utilizes the same neoantigen delivery system as GRANITE but contains a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing us with an off-the-shelf alternative to GRANITE. SLATE is being evaluated in the Phase 2 portion of a Phase I/2 clinical study in combination with checkpoint inhibitors for the treatment of non-small cell ...
-
Gritstone - Bispecific Antibody Therapeutic (BiSAb)
Gritstone has a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. Our lead BiSAb candidate is currently in IND-enabling studies. The target of this lead program is CT83, a cancer-germline antigen which is highly expressed on certain solid tumors and has limited/low expression on normal ...
-
Gritstone - Model EDGE - Cancer Cell Therapies
We are leveraging EDGE to define targets for T-cell receptor (TCR) directed cell therapies. These additional targets that were identified and validated by Gritstone EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using these highly specific ...
-
CORAL - COVID-19 Second Generation Vaccine
Gritstone is developing a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency, including against emerging Spike mutant forms of ...
-
Gritstone - HIV Therapeutic Vaccine
We have a collaboration established with Gilead Sciences to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to cure patients with human immunodeficiency virus (HIV) infection. The companies are developing an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (samRNA) and adenoviral ...